These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 38714351)

  • 1. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; To F; Jeong AD; Guntupalli SR; Behbakht K; Gibaja V; Arnoult N; Cocozaki A; Chuong EB; Bitler BG
    Mol Cancer Ther; 2024 May; ():. PubMed ID: 38714351
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combining EHMT and PARP Inhibition: A Strategy to Diminish Therapy-Resistant Ovarian Cancer Tumor Growth while Stimulating Immune Activation.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; To F; Jeong AD; Guntupalli SR; Behbakht K; Gibaja V; Arnoult N; Cocozaki A; Chuong EB; Bitler BG
    Mol Cancer Ther; 2024 Jun; ():OF1-OF16. PubMed ID: 38863225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; Jeong AD; Guntupalli SR; Behbakht K; Gbaja V; Arnoult N; Chuong EB; Bitler BG
    bioRxiv; 2023 Feb; ():. PubMed ID: 36865165
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone methyltransferases EHMT1 and EHMT2 (GLP/G9A) maintain PARP inhibitor resistance in high-grade serous ovarian carcinoma.
    Watson ZL; Yamamoto TM; McMellen A; Kim H; Hughes CJ; Wheeler LJ; Post MD; Behbakht K; Bitler BG
    Clin Epigenetics; 2019 Nov; 11(1):165. PubMed ID: 31775874
    [TBL] [Abstract][Full Text] [Related]  

  • 5. STING agonism overcomes STAT3-mediated immunosuppression and adaptive resistance to PARP inhibition in ovarian cancer.
    Ding L; Wang Q; Martincuks A; Kearns MJ; Jiang T; Lin Z; Cheng X; Qian C; Xie S; Kim HJ; Launonen IM; Färkkilä A; Roberts TM; Freeman GJ; Liu JF; Konstantinopoulos PA; Matulonis U; Yu H; Zhao JJ
    J Immunother Cancer; 2023 Jan; 11(1):. PubMed ID: 36609487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EHMT1/2 Inhibition Promotes Regression of Therapy-Resistant Ovarian Cancer Tumors in a CD8 T-cell-Dependent Manner.
    Nguyen LL; Watson ZL; Ortega R; Woodruff ER; Jordan KR; Iwanaga R; Yamamoto TM; Bailey CA; To F; Lin S; Villagomez FR; Jeong AD; Guntupalli SR; Behbakht K; Gibaja V; Arnoult N; Chuong EB; Bitler BG
    Mol Cancer Res; 2024 Dec; 22(12):1117-1127. PubMed ID: 39136655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PARP Inhibition Activates STAT3 in Both Tumor and Immune Cells Underlying Therapy Resistance and Immunosuppression In Ovarian Cancer.
    Martincuks A; Song J; Kohut A; Zhang C; Li YJ; Zhao Q; Mak E; Rodriguez-Rodriguez L; Yu H; Cristea M
    Front Oncol; 2021; 11():724104. PubMed ID: 34956861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Activation of Wnt signaling promotes olaparib resistant ovarian cancer.
    Yamamoto TM; McMellen A; Watson ZL; Aguilera J; Ferguson R; Nurmemmedov E; Thakar T; Moldovan GL; Kim H; Cittelly DM; Joglar AM; Brennecke EP; Wilson H; Behbakht K; Sikora MJ; Bitler BG
    Mol Carcinog; 2019 Oct; 58(10):1770-1782. PubMed ID: 31219654
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PARP1-DOT1L transcription axis drives acquired resistance to PARP inhibitor in ovarian cancer.
    Liu C; Li J; Xu F; Chen L; Ni M; Wu J; Zhao H; Wu Y; Li J; Wu X; Chen X
    Mol Cancer; 2024 May; 23(1):111. PubMed ID: 38778348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improving PARP inhibitor efficacy in high-grade serous ovarian carcinoma: A focus on the immune system.
    Bound NT; Vandenberg CJ; Kartikasari AER; Plebanski M; Scott CL
    Front Genet; 2022; 13():886170. PubMed ID: 36159999
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 12. CBL0137 impairs homologous recombination repair and sensitizes high-grade serous ovarian carcinoma to PARP inhibitors.
    Lu X; He Y; Johnston RL; Nanayakarra D; Sankarasubramanian S; Lopez JA; Friedlander M; Kalimutho M; Hooper JD; Raninga PV; Khanna KK
    J Exp Clin Cancer Res; 2022 Dec; 41(1):355. PubMed ID: 36539830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
    Tattersall A; Ryan N; Wiggans AJ; Rogozińska E; Morrison J
    Cochrane Database Syst Rev; 2022 Feb; 2(2):CD007929. PubMed ID: 35170751
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ATF6-Mediated Signaling Contributes to PARP Inhibitor Resistance in Ovarian Cancer.
    McMellen A; Yamamoto TM; Qamar L; Sanders BE; Nguyen LL; Ortiz Chavez D; Bapat J; Berning A; Post MD; Johnson J; Behbakht K; Nurmemmedov E; Chuong EB; Bitler BG
    Mol Cancer Res; 2023 Jan; 21(1):3-13. PubMed ID: 36149636
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression.
    Jiao S; Xia W; Yamaguchi H; Wei Y; Chen MK; Hsu JM; Hsu JL; Yu WH; Du Y; Lee HH; Li CW; Chou CK; Lim SO; Chang SS; Litton J; Arun B; Hortobagyi GN; Hung MC
    Clin Cancer Res; 2017 Jul; 23(14):3711-3720. PubMed ID: 28167507
    [No Abstract]   [Full Text] [Related]  

  • 16. KAT6A Condensates Impair PARP1 Trapping of PARP Inhibitors in Ovarian Cancer.
    Zhan Z; Zhang J; Liang H; Wang C; Hong L; Liu W
    Adv Sci (Weinh); 2024 Sep; 11(34):e2400140. PubMed ID: 38973255
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic.
    Cerrato A; Morra F; Celetti A
    J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDC7 Inhibition Potentiates Antitumor Efficacy of PARP Inhibitor in Advanced Ovarian Cancer.
    Liu S; Deng P; Yu Z; Hong JH; Gao J; Huang Y; Xiao R; Yin J; Zeng X; Sun Y; Wang P; Geng R; Chan JY; Guan P; Yu Q; Teh BT; Jiang Q; Xia X; Xiong Y; Chen J; Huo Y; Tan J
    Adv Sci (Weinh); 2024 Dec; 11(45):e2403782. PubMed ID: 39412086
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomic and expressional dynamics of ovarian cancer cell lines in PARPi treatment revealed mechanisms of acquired resistance.
    Cheng A; Rao Q; Liu Y; Huang C; Li J; Huo C; Lin Z; Lu H
    Gynecol Oncol; 2022 Dec; 167(3):502-512. PubMed ID: 36270832
    [TBL] [Abstract][Full Text] [Related]  

  • 20. OPERA: a phase II trial of oregovomab plus non-platinum chemotherapy in PARP inhibitor/platinum-resistant ovarian cancer.
    Park J; Cho HW; Lim MC; Choi CH; Lee JY
    Future Oncol; 2024; 20(26):1893-1899. PubMed ID: 38940373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.